Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.

Servicio de Endocrinología y Nutrición, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
Obesity Surgery (Impact Factor: 3.1). 09/2009; 19(11):1574-80. DOI: 10.1007/s11695-009-9955-y
Source: PubMed

ABSTRACT The physiological role of apelin in obesity and diabetes remains unclear. Although apelin has been studied in persons with different conditions, no studies have yet examined the joint influence of obesity and diabetes on apelin levels. We measured the changes in apelin levels in morbidly obese subjects, with and without diabetes, and in the inverse situation of improvement in carbohydrate metabolism as a result of bariatric surgery.
The study was undertaken in 54 morbidly obese persons, 16 of whom had type 2 diabetes mellitus, before and 7 months after undergoing bariatric surgery, and in 12 healthy, nonobese persons. Measurements were made of apelin levels and insulin sensitivity by an intravenous glucose tolerance test.
The apelin levels in the morbidly obese patients prior to surgery were significantly higher than those of the controls only when the morbidly obese subjects were diabetic (P < 0.005). Apelin levels correlated significantly in the morbidly obese patients with serum triglycerides (r = 0.292, P = 0.032) and glucose (r = 0.337, P = 0.039). Bariatric surgery resulted in a significant decrease in apelin levels only in the morbidly obese subjects with impaired fasting glucose or diabetes. The change in apelin levels correlated significantly in the morbidly obese patients with the changes in serum glucose (r = 0.338, P = 0.038) and insulin sensitivity (r = -0.417, P = 0.043).
This study demonstrates that obesity is not the main determinant of the rise in apelin levels. The association between apelin levels and glucose concentrations and insulin sensitivity provides evidence that apelin may play a role in the pathogenesis of diabetes.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The prevalence of obesity has increased dramatically in the last decades both in children and adults and is now considered a major health problem. It is associated with numerous comorbidities such as hypertension, dyslipidemia, diabetes and subsequent cardiovascular disease (CVD). One of the mechanisms that connect obesity with these comorbidities is the secretion of so-called adipocytokines or adipokines by the adipose tissue itself. Most adipokines with pro-inflammatory properties are overproduced with increasing adiposity, whereas some adipokines with anti-inflammatory or insulin-sensitizing properties, like adiponectin, are decreased. This dysregulation of adipokines production may promote obesity-linked metabolic disorders and CVD. Except adipokines a wide complex network of chemicals balances pro-inflammatory and anti-inflammatory effects. Areas covered: In this review, we summarize the role of various adipokines and other chemicals associated with obesity and its related cardiometabolic comorbidities, with a special focus on recent evidence showing their potential role as biomarkers whose expression are indicative of obesity and its complications. Expert opinion: Biomarkers associated with obesity, type 2 diabetes (T2D) and CVD could prove beneficial for early identification, proper treatment and good life assurance. Unfortunately, the complexity of biological pathways interactions is such that further research is necessary before any of these markers could reach an accurate diagnostic value.
    Expert opinion on therapeutic targets 01/2014; · 3.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has recently been demonstrated that the apelin receptor (APJ) plays a significant role in mediating the stretch response within the heart in a G-protein-independent and β-arrestin-dependent fashion. This discovery adds to the consolidated literature describing the potential benefits of APJ agonists. In this review, the authors will examine the functional selectivity of APJ and stretch with respect to their ability to signal via both G-protein-dependent and G-protein-independent mechanisms, with a focus on the multifunctional protein, β-arrestin. The possibility of selecting or designing novel ligands that differentially activate only a subset of functions via a single receptor holds great promise for the treatment of diseases such as heart failure and hypertension. Finally, hypothetical approaches to target APJ, taking into account its downstream pathways, will be described.
    Expert Review of Cardiovascular Therapy 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The dramatic worldwide increase in the prevalence of diabetes has generated an attempt by the scientific community to identify strategies for its treatment and prevention. Vascular dysfunction is a hallmark of diabetes and frequently leads to the development of atherosclerosis, coronary disease-derived myocardial infarction, stroke, peripheral arterial disease and diabetic “triopathy” (retinopathy, nephropathy and neuropathy). These vascular complications, developing in an increasingly younger cohort of diabetic patients, contribute to morbidity and mortality. Despite the development of new anti-diabetic or anti-hyperglycemic drugs; however, vascular complications remain to be a problem. This warrants a need for new therapeutic strategies to tackle diabetic vasculopathy. There is a growing body of evidence showing that peptide-binding G protein-coupled receptors (peptide-biding GPCRs) play an important role in the pathophysiology of vascular dysfunction during diabetes. Thus, in this review, we discuss some of the peptide-binding GPCRs involved in the regulation of vascular function that have potential to be a therapeutic target in the treatment of diabetic vasculopathy.This article is protected by copyright. All rights reserved.
    Acta Physiologica 03/2014; · 4.38 Impact Factor